We are live on ! Find out more
ANIK icon

Anika Therapeutics

13.23 USD
-0.05
0.38%
At close Updated Nov 20, 4:00 PM EST
1 day
-0.38%
5 days
-2.58%
1 month
-35.27%
3 months
-38%
6 months
-12.62%
Year to date
41.5%
1 year
42.26%
5 years
-66.76%
10 years
-71.25%
 

About: Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Employees: 235

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 50%
Neutral 37.5%
Negative 12.5%
Neutral
Seeking Alpha
16 days ago
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Negative
MarketBeat
16 days ago
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
Anika Therapeutics NASDAQ: ANIK reported a 10% increase in third-quarter revenue and raised the lower end of its 2026 revenue and adjusted EBITDA margin forecasts, even as it lowered its commercial channel growth outlook following slower U.S. elective surgery activity.
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
Positive
Zacks Investment Research
16 days ago
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.04 per share a year ago.
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
16 days ago
Anika Reports Third Quarter 2026 Financial Results
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.
Anika Reports Third Quarter 2026 Financial Results
Neutral
GlobeNewsWire
1 month ago
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
Positive
Zacks Investment Research
1 month ago
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Positive
Zacks Investment Research
2 months ago
Best Momentum Stocks to Buy for August 26th
BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
Best Momentum Stocks to Buy for August 26th
Positive
Zacks Investment Research
3 months ago
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Positive
Zacks Investment Research
3 months ago
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
Positive
Zacks Investment Research
3 months ago
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Price charts implemented using Lightweight Charts™